Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerzy Jankun

Showing results (11-20 of 65) with videos related to

Pageof 7
Sort By:
International Journal of Molecular Medicine|September 10, 2003
Inhibition of lipoxygenase by (-)-epigallocatechin gallate: X-ray analysis at 2.1 A reveals degradation of EGCG and shows soybean LOX-3 complex with EGC insteadEwa Skrzypczak-Jankun, Kangjing Zhou, Jerzy Jankun
International Journal of Molecular Medicine|January 15, 2013
Plasminogen activator inhibitor-1 in kidney pathology (Review)Sylwia Małgorzewicz, Ewa Skrzypczak-Jankun, Jerzy Jankun
International Journal of Molecular Medicine|October 14, 2011
Can inactivators of plasminogen activator inhibitor alleviate the burden of obesity and diabetes? (Review)Jerzy Jankun, Abdulrahman Al-Senaidy, Ewa Skrzypczak-Jankun
The Prostate|February 17, 2006
Vascular endothelial growth factor production in human prostate cancer cells is stimulated by overexpression of platelet 12-lipoxygenaseN Patrick McCabe, Steven H Selman, Jerzy Jankun
International Journal of Oncology|November 14, 2013
Epigallocatechin-3-gallate prevents tumor cell implantation/growth in an experimental rat bladder tumor modelJerzy Jankun, Rick W Keck, Steven H Selman
Central-European Journal of Immunology|July 9, 2015
Synergistic anticancer activity of biologicals from green and black tea on DU 145 human prostate cancer cellsAndrew J Kobalka, Rick W Keck, Jerzy Jankun
Experimental and Therapeutic Medicine|July 3, 2015
Comparison between the clot-protecting activity of a mutant plasminogen activator inhibitor-1 with a very long half-life and 6-aminocaproic acidDaniel Glenn Kindell, Rick Wayne Keck, Jerzy Jankun
Acta Crystallographica. Section D, Biological Crystallography|March 3, 2004
Soybean lipoxygenase-3 in complex with 4-nitrocatecholEwa Skrzypczak-Jankun, Oleg Y Borbulevych, Jerzy Jankun
International Journal of Molecular Medicine|May 13, 2004
Plasminogen activator inhibitor type-1: its structure, biological activity and role in tumorigenesis (Review)Joanna Chorostowska-Wynimko, Ewa Skrzypczak-Jankun, Jerzy Jankun
Oncology Letters|December 19, 2013
Analysis of the anticancer activity of curcuminoids, thiotryptophan and 4-phenoxyphenol derivativesShireen Parsai, Rick Keck, Ewa Skrzypczak-Jankun, et al.
Pageof 7

Showing results (11-20 of 65) with videos related to

Sort By:
Pageof 7
International Journal of Molecular Medicine|September 10, 2003
Inhibition of lipoxygenase by (-)-epigallocatechin gallate: X-ray analysis at 2.1 A reveals degradation of EGCG and shows soybean LOX-3 complex with EGC insteadEwa Skrzypczak-Jankun, Kangjing Zhou, Jerzy Jankun
International Journal of Molecular Medicine|January 15, 2013
Plasminogen activator inhibitor-1 in kidney pathology (Review)Sylwia Małgorzewicz, Ewa Skrzypczak-Jankun, Jerzy Jankun
International Journal of Molecular Medicine|October 14, 2011
Can inactivators of plasminogen activator inhibitor alleviate the burden of obesity and diabetes? (Review)Jerzy Jankun, Abdulrahman Al-Senaidy, Ewa Skrzypczak-Jankun
The Prostate|February 17, 2006
Vascular endothelial growth factor production in human prostate cancer cells is stimulated by overexpression of platelet 12-lipoxygenaseN Patrick McCabe, Steven H Selman, Jerzy Jankun
International Journal of Oncology|November 14, 2013
Epigallocatechin-3-gallate prevents tumor cell implantation/growth in an experimental rat bladder tumor modelJerzy Jankun, Rick W Keck, Steven H Selman
Central-European Journal of Immunology|July 9, 2015
Synergistic anticancer activity of biologicals from green and black tea on DU 145 human prostate cancer cellsAndrew J Kobalka, Rick W Keck, Jerzy Jankun
Experimental and Therapeutic Medicine|July 3, 2015
Comparison between the clot-protecting activity of a mutant plasminogen activator inhibitor-1 with a very long half-life and 6-aminocaproic acidDaniel Glenn Kindell, Rick Wayne Keck, Jerzy Jankun
Acta Crystallographica. Section D, Biological Crystallography|March 3, 2004
Soybean lipoxygenase-3 in complex with 4-nitrocatecholEwa Skrzypczak-Jankun, Oleg Y Borbulevych, Jerzy Jankun
International Journal of Molecular Medicine|May 13, 2004
Plasminogen activator inhibitor type-1: its structure, biological activity and role in tumorigenesis (Review)Joanna Chorostowska-Wynimko, Ewa Skrzypczak-Jankun, Jerzy Jankun
Oncology Letters|December 19, 2013
Analysis of the anticancer activity of curcuminoids, thiotryptophan and 4-phenoxyphenol derivativesShireen Parsai, Rick Keck, Ewa Skrzypczak-Jankun, et al.
Pageof 7